2. Academic Validation
  3. Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer

Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer

  • Bioorg Chem. 2022 Apr;121:105659. doi: 10.1016/j.bioorg.2022.105659.
Deping Li 1,  Wenwu Liu 2,  Yaoguan Huang 2,  Mingyue Liu 3,  Caizhi Tian 2,  Hongyuan Lu 4,  Hui Jia 5,  Zihua Xu 6,  Huaiwei Ding 7,  Qingchun Zhao 8
Affiliations

Affiliations

  • 1 School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China; Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, People's Republic of China.
  • 2 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
  • 3 School of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
  • 4 School of Pharmacy, China Medical University, Shenyang 110016, People's Republic of China.
  • 5 Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
  • 6 School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China.
  • 7 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China. Electronic address: [email protected].
  • 8 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People's Republic of China. Electronic address: [email protected].
PMID: 35180487 DOI: 10.1016/j.bioorg.2022.105659
Abstract

Cyclin-dependent kinase 4 (CDK4), which is involved in dynamic regulation of cell cycle, has gained particularly attention for its role in controlling tumor growth.Increasing evidence showed that β-carboline derivatives have the potential to inhibit CDK4. Herein, on the basis of previous work, we designed and synthesized a series of novel β-carbolines and evaluated their antitumor activity.Among them, compounds ZDLD13 and ZDLD20, with the most potent anti-proliferative activity and CDK4 enzymatic inhibition activity, were selected for further pharmacological research in vitro and in vivo. The results in vitro showed that ZDLD13 and ZDLD20 exhibited potent anti-HCT116 activityincluding inhibition of colony formation, inhibition of invasion and migration, inducing of Apoptosis, and arresting of G1 phase in cell cycle.In vivo,ZDLD13showed significant tumor growth inhibition in HCT116 tumor xenograft model without causing significant weight loss and toxicityconsistent with the acute toxicity test. In addition, silico study showed ZDLD13 and ZDLD20 not only have good biological actions, but also acceptable predicted ADME and physicochemical properties.Taken together, compoundsZDLD13and ZDLD20 could be selected for further modification and preclinical evaluation.

Keywords

CDK4; HCT116; Harmine; β-carboline.

Figures
Products